RxSight (RXST) Net Cash Flow Growth (1y) (2021 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -562.50% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -564.44% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 76.43% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -31.84% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -394.13% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 57.36% |
| 10 | RxSight | 215.82 Mn | -2.06 Mn | 23.50 Mn | -121.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -121.08% |
| Dec 31, 2025 | -26,952.78% |
| Sep 30, 2025 | -38.66% |
| Jun 30, 2025 | 250.52% |
| Mar 31, 2025 | -50.83% |
| Dec 31, 2024 | 120.81% |
| Sep 30, 2024 | -830.12% |
| Jun 30, 2024 | -262.79% |
| Mar 31, 2024 | 2,886.04% |
| Dec 31, 2023 | -106.05% |
| Sep 30, 2023 | 107.02% |
| Jun 30, 2023 | -107.64% |
| Mar 31, 2023 | 97.25% |
| Dec 31, 2022 | 106.55% |
| Sep 30, 2022 | -156.81% |
| Jun 30, 2022 | 69.67% |
| Mar 31, 2022 | -388.04% |
| Dec 31, 2021 | -2,854.83% |
| Sep 30, 2021 | 5,507.54% |